Article

Bbarrons.com on 2019-10-23 14:36

Eli Lilly Earned More Than Expected. Here’s Why the Stock Is Falling Anyway.

Sales of Taltz, a key Lilly drug that is facing increased competition from other anti-inflammatories, missed analysts’ expectations.

Related news

BEli Lilly Reports Earnings Tomorrow. Here’s What to Expect.barrons.com
Wall Street
BEli Lilly Stock Is Up as Earnings Edge Past Expectations barrons.com
Stock Island
BEli Lilly Stock Rises as Earnings Guidance Beats Analyst Expectations barrons.com
Wall Street
BEli Lilly Stock Falls as Sales Disappoint. Analyst Welcomes Diabetes Data.barrons.com
Wall Street
BEli Lilly Cuts Earnings Forecast as Profits Fall Short barrons.com
Eli Lilly michronicleonline.com
Puerto Rico
Eli Lilly, Urban Outfitters skid; Deere climbs The Salt Lake Tribune
Wall Street , New York
CFO Moves: Eli Lilly, Dunkin’ Brands Group blogs.wsj.com
Wall Street
Eli Lilly ends drug development, stock plunges USA today
Wall Street , Indianapolis
MEli Lilly (LLY) earnings This fall 2023 mvtelegraph.com
Wall Street , California , San Diego
BEli Lilly Stock Climbs After a Glowing Earnings Report barrons.com
BBest Buy Earned More Than Expected. The Stock Is Falling Anyway.barrons.com
Stock Island
MPfizer enters weight reduction drug market with Novo Nordisk, Eli Lilly mvtelegraph.com
Wall Street
MNovo Nordisk, Eli Lilly are tackling provide points mvtelegraph.com
France , Denmark , Indiana , Germany , Triangle Park
BJohnson & Johnson’s Earnings Were Good Enough for Wall Street Analysts. The Stock Is Falling Anyway.barrons.com
Stock Island , Wall Street
Eli Lilly 2015 forecast falls short of Street expectations elkharttruth.com
Indianapolis , Switzerland , Wall Street
Slipping COVID-19 treatment demand hits Eli Lilly forecast Seattle Times
United States , Wall Street , Indianapolis
MBiogen, Eli Lilly earnings beats push industry stocks up marketwatch.com
New York , Wall Street